1.Research progress on the intervention of traditional Chinese medicine monomer and formula in the mTOR signaling pathway for the treatment of osteoporosis
Yan CHEN ; Liufeng SHAN ; Wensheng CHE ; Yujun LIU ; Zhiqi LIU ; Xiaoxue SHI ; Zhihai FENG
China Pharmacy 2023;34(23):2934-2938
Osteoporosis is an important cause of bone weakness and susceptibility to fractures. Anti-osteoporosis drugs of Western medicine cannot reverse its progression, and can only reduce the loss of bone density; long-term use of them is accompanied by certain adverse reactions. Traditional Chinese medicine focuses on syndrome differentiation and holistic approach, which can make up for the shortcomings of Western medicine’s treatment. The mammalian target of rapamycin (mTOR) signaling pathway is involved in the growth, proliferation, and differentiation of bone cells, and is closely related to the occurrence and development of osteoporosis. In recent years, various traditional Chinese medicine monomers (such as flavonoids, polysaccharides, alkaloids, etc.) and traditional Chinese medicine formulas (such as Bushen huoxue decoction, Liuwei dihuang pills, Erzhi pills, etc.) have been proven to promote bone formation, inhibit bone resorption, enhance bone cell autophagy, and delay the progression of osteoporosis by regulating the mTOR signaling pathway. Therefore, the article summarizes the traditional Chinese medicine monomer and formula that intervene in the mTOR signaling pathway for the treatment of osteoporosis, in order to provide medication ideas for the traditional Chinese medicine treatment of osteoporosis.